Drug Database
FL

fluticasone propionate + formoterol fumarate dihydrate

✓ Approved

Vectura Group Ltd · ADRB2 · 小分子

什么是 fluticasone propionate + formoterol fumarate dihydrate?

fluticasone propionate + formoterol fumarate dihydrate 是一种小分子,由Vectura Group Ltd研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled。

药物档案

公司Vectura Group Ltd
药物类别小分子
分子靶点ADRB2, NR3C1
给药途径Inhaled
状态Approved

作用机制

分子靶点

fluticasone propionate + formoterol fumarate dihydrate 作用于 2 个分子靶点:

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fluticasone propionate + formoterol fumarate dihydrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedFrontiers in nephrology2026-11-18

Oral ferrous fumarate dosing regimens in peritoneal dialysis: a single-center retrospective audit.

Tijs Annie M AM, Rawee Pien P, Yang Yaqin Y, Manson Nienke A NA et al.

Anemia is highly prevalent in patients with kidney failure receiving peritoneal dialysis (PD). Oral iron supplementation is frequently prescribed, but adherence may be limited by pill burden and gastrointestinal adverse effects. Emerging evidence suggests that less frequent oral iron dosing may enhance iron absorption by reducing hepcidin-mediated inhibition, yet data in PD patients are lacking. We evaluated iron utilization and compared the effectiveness of different oral iron regimens in PD patients. This retrospective cohort study (2007-2025) included adults (≥18 years) receiving peritoneal dialysis at the Dialysis Center Groningen who were treated with oral ferrous fumarate for ≥3 months. Patients receiving intravenous iron, other iron formulations, non-standard dosing regimens, or with active gastrointestinal bleeding were excluded. Ferrous fumarate regimens included 200 mg once daily (OD), twice daily (BID), three times daily (TID), or three times weekly (TIW). Patients not receiving oral iron were evaluated for treatment eligibility. Primary outcomes were 6-month changes in hemoglobin, ferritin, and transferrin saturation. Regimen-specific trajectories were analyzed using linear mixed-effects models. Sensitivity analyses adjusted for age, sex, erythropoiesis-stimulating agent dose, and inflammation, and were restricted to incident iron users on PD. Of the 140 patients screened, 85 patients were included (median age 61 years; 57.6% male). TIW dosing resulted in hemoglobin trajectories comparable to OD dosing (P = 0.30), with similar ferritin and transferrin saturation trajectories. In contrast, BID dosing was associated with a steeper hemoglobin increase (0.013 g/dL/day; P = 0.001) than OD dosing. Sensitivity analyses yielded similar results. Among patients not receiving iron therapy, 30% (n= 9/30) met contemporaneous guideline criteria for treatment. In this 18-year retrospective study of 85 PD patients, TIW and OD oral iron supplementation produced comparable hematologic outcomes, suggesting that less frequent dosing may represent an effective strategy to reduce treatment burden without compromising efficacy. Twice-daily dosing was associated with faster hemoglobin increases, likely reflecting greater cumulative iron exposure. Iron therapy was underutilized in a substantial proportion of eligible patients. Although limited by the modest sample size, these findings highlight the need for expert consensus to address evidence gaps and guide anemia management in PD.

PMID 43047316
阅读全文 →
PubMedFrontiers in neurology2026-11-18

Dimethyl fumarate in the treatment of multiple sclerosis: real-world effectiveness in a Turkish cohort.

Şen Sedat S, Beckmann Yeşim Y, Karabudak Rana R, Arslan Gökhan G et al.

Dimethyl fumarate (DMF) is approved as a first-line treatment in relapsing-remitting multiple sclerosis (RRMS). To evaluate the demographic, clinical, and radiological outcomes of DMF treatment in a real-world setting. Multicenter retrospective study based on data from 61 clinics across Türkiye. Side effects, leukocyte and lymphocyte counts, liver enzymes, EDSS (Expanded Disability Status Scale), and upper- and lower-extremity test results were evaluated in patients with RRMS before DMF initiation and at 1, 6, 12, and 24 months. Additionally, NEDA-3 (No Evidence of Disease Activity-3) status was assessed at the 1 and 2-year follow-ups. 1,749 patients participated in this retrospective study. The most common side effects were flushing and gastrointestinal symptoms, which were more frequent in women and in patients with lower weight and lower Body Mass Index (BMI). Leukocyte and lymphocyte counts initially decreased and then stabilized, whereas transient elevations in liver enzymes resolved during follow-up. EDSS scores showed a significant improvement beginning at the 6-month follow-up. Performance on the Nine-Hole Peg Test (9HPT) improved, whereas no significant change was observed in the Timed 25-Foot Walk (T25FW). In addition, approximately 70% of the patients achieved NEDA-3 status at both the 1 and 2-year follow-ups. DMF demonstrated a favorable safety profile and was associated with significant improvements in EDSS while maintaining NEDA-3 status in approximately 70% of patients with RRMS. Adverse events occurred more frequently among women and among patients with lower body weight and lower BMI.

PMID 43047475
阅读全文 →
PubMedJournal of proteomics2026-11-18

Comprehensive metabolomics and proteomics reveal differences in metabolic networks among distinct rat models of benign prostatic hyperplasia.

Xu Chenxi C, Xu Rui R, Dong Yidian Y, Wang Yao Y et al.

Benign prostatic hyperplasia (BPH) is associated with multiple etiological factors, but the molecular differences among BPH models induced by distinct pathological drivers remain unclear. Here, we established three rat BPH models, including a testosterone propionate (TP)-induced model, a high-fat/high-sugar diet (HFS)-induced model, and a combined HFS plus TP (HFS-TP) model. Untargeted metabolomics and quantitative proteomics were integrated to compare shared and model-specific molecular alterations in prostate tissues. All three models showed typical BPH-like histopathological changes. Multi-omics analysis revealed distinct remodeling patterns among the models. The TP model was mainly characterized by androgen-associated metabolic alterations with limited proteomic disturbance, whereas the HFS model showed more evident immune-inflammatory, oxidative stress-related, and extracellular matrix-associated proteomic changes. The HFS-TP model exhibited the broadest molecular disturbance, involving lipid-associated metabolism, glycan-related metabolism, glutathione-related redox regulation, and structural remodeling. Despite these differences, all models shared pathway-level alterations involving amino acid metabolism, unsaturated fatty acid biosynthesis, cytokine-cytokine receptor interaction, JAK-STAT signaling, glutathione metabolism, cytoskeleton organization, cell adhesion, and calcium signaling. Integrated gene-metabolite interaction network analysis identified L-glutamic acid as a database-supported candidate connecting node between metabolomic and proteomic alterations. These findings provide a comparative multi-omics framework for understanding molecular heterogeneity in BPH. SIGNIFICANCE: Benign prostatic hyperplasia is driven by multiple etiological factors, whereas different experimental BPH models may capture distinct aspects of disease-related molecular remodeling. This study provides a comparative multi-omics analysis of testosterone propionate-induced, high-fat/high-sugar diet-induced, and combined diet-androgen-induced BPH rat models. The high-fat/high-sugar dietary intervention better reflects Western diet-related obesogenic exposure, while the combined HFS-TP model produced the broadest metabolomic and proteomic remodeling. By integrating untargeted metabolomics with DIA-based quantitative proteomics, this study reveals both shared alterations in amino acid metabolism, lipid-associated metabolism, inflammatory signaling, redox regulation, and structural remodeling, as well as model-specific molecular characteristics. These findings provide a systems-level framework for understanding BPH model heterogeneity and may help researchers select appropriate animal models for mechanistic, pharmacological, and multi-omics studies of BPH.

PMID 43051617
阅读全文 →
PubMedISME communications2026-11-18

Lactate:propionate molar ratio and substrate concentrations shape valerate production in secondary lactate fermentations.

Estévez Ángel Á, Ganigué Ramon R

Odd-chain carboxylates such as valerate and heptanoate are ecologically relevant metabolites and promising platform chemicals, yet the factors leading to their formation during secondary lactate fermentations remain poorly understood. Here, a continuous anaerobic bioreactor was operated for 297 days at pH 5.5 to evaluate how lactate:propionate molar ratios shape product spectrum in lactate fermentations. Valerate was the predominant odd-chain product under all conditions, reaching concentrations up to 110 mM, while heptanoate accumulated only at low levels (<10 mM). At low lactate concentrations (110-220 mM), product selectivity strongly depended on the lactate:propionate ratio. When lactate:propionate ratios were around 1.2 mol/mol, odd-chain products were favored, whereas higher ratios (up to 4.8 mol/mol) shifted metabolism toward caproate and butyrate formation. However, this trend was not maintained at higher lactate concentrations (330-440 mM; lactate not fully consumed), where odd-chain selectivities remained high even at lactate:propionate ratios of 4.8 mol/mol. Pathway analysis allowed to infer that under high-lactate conditions, up to 30% of lactate was used for propionate and acetate formation. Microbial community analysis revealed a stable dominance of Caproiciproducens spp. when valerate was the main product. Overall, this work provides mechanistic insights into the ecology of lactate fermentations and offers a framework for steering product selectivity in engineered anaerobic systems.

PMID 43047724
阅读全文 →
PubMedApplied and environmental microbiology2026-11-18

Hydrogen-dependent sulfur and iron reduction by marine thermophiles as analogs for early Earth and ocean world processes.

Holden James F JF, Scott Nathaniel M NM, Roberts Alexander D AD, Nishshankage Kulathi T KT

Life on the early Earth was likely anaerobic, H2 dependent, CO2 fixing, and thermophilic in a marine hydrothermal setting. Geochemical and mineral evidence suggests that sulfur and iron respiration occurred during the Paleoarchean (3.6-3.2 Ga). However, the predominant mechanisms of H2-dependent sulfur and iron respiration in hydrothermal systems, then or now, have yet to be elucidated. Studying these processes in microorganisms from modern hydrothermal systems provides context for interpreting the characteristics of life during the Paleoarchaean. All the bacteria and archaea that have been cultured and characterized as extremely thermophilic, marine, H2 dependent, and sulfur reducing or iron reducing (36 species) were surveyed for genes related to energy generation and terminal reduction processes. Respiratory hydrogenases, Nuo-like complexes, and ATP synthases were all universally conserved. These data, coupled with phenotypic and biochemical information, suggest that these organisms oxidize H2 outside the cytoplasmic membrane, reduce menaquinone, and generate a proton motive force for ATP synthesis. The most conserved sulfur reduction gene encoded a cytoplasmic NAD(P)H sulfur reductase. Genes encoding cytoplasmic hydrogenases and membrane-bound pyranopterin oxidoreductases were also common. The widespread conservation of menaquinol-dependent fumarate reductase points to CO2 assimilation as another means of electron disposal, with excess reductant possibly used to drive sulfur or iron reduction. Understanding the metabolic potential of H2-dependent marine thermophiles deepens our knowledge of life in hydrothermal systems and contributes to the interpretation of data from ocean world missions.

PMID 43049343
阅读全文 →
PubMedJournal of anaesthesiology, clinical pharmacology2026-11-18

Efficacy of a single dose of postoperative intravenous iron on erythropoietic recovery for Return to Intended Oncological Therapy in patients with head and neck cancer: A randomized controlled trial.

Rajan Sunil S, Thomas Neha N, Paul Jerry J, Prasad Aishwarya A et al.

Perioperative anemia is a critical barrier to Return to Intended Oncological Therapy (RIOT) in head and neck cancer (HNC) patients. Surgery-induced systemic inflammation triggers a hepcidin surge, causing functional iron deficiency that limits erythropoiesis and delays recovery.We compared the efficacy of a single postoperative dose of intravenous versus oral iron therapy in elevating hemoglobin (Hb) concentrations at RIOT, typically occurring within the 4-6 week postsurgical window. In this prospective, single-blinded, randomized trial, 80 HNC patients who underwent major resection and reconstruction surgery with postoperative day (POD) 1 Hb <10 g/dL were recruited. Group A received 200 mg daily oral ferrous fumarate via nasogastric tube. Group B received a single dose of 1000 mg IV ferric carboxymaltose on POD 1. At 4-6 weeks, intergroup analysis showed no significant difference in absolute Hb levels (Group A: 10.91 ± 1.56 vs. Group B: 10.94 ± 1.05 g/dL; P = 0.907). However, intragroup analysis revealed a significant increase in Hb levels in both arms (P < 0.001). The intergroup comparison of increase in Hb levels from POD 1 to 4-6 weeks recovery period showed that Group B achieved a significantly higher mean Hb increase compared to Group A (+2.07 vs. +1.52 g/dL; P = 0.002). A single postoperative dose of 1000 mg IV ferric carboxymaltose showed no superiority over oral iron in 4-6 week Hb levels or RIOT timing. IV iron achieved a significantly higher mean Hb increase compared to oral iron (+2.07 vs. +1.52 g/dL), but oral adherence was low.

PMID 43048720
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多fluticasone propionate + formoterol fumarate dihydrate